Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 6 minute read Pharma Industry News Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets. byVenkateshOctober 30, 2025